{
  "docId": "019de074-23ea-7254-b381-db7aadcb5c1d",
  "docSlug": "cf70c7f99b18feee93f81e87108bc323",
  "documentTitle": "AbCellera | Investor Conference Presentation Deck | 19 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 19,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a molecular structure background and a list-based layout to show the progression of the partnership.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-23ea-7254-b381-db7aadcb5c1d/13",
  "deckHref": "/decks/019de074-23ea-7254-b381-db7aadcb5c1d",
  "deckJsonHref": "/decks/019de074-23ea-7254-b381-db7aadcb5c1d.json",
  "deckAnchorHref": "/decks/019de074-23ea-7254-b381-db7aadcb5c1d#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.38,
        "x": 0.58,
        "y": 0.13
      },
      "kind": "list",
      "text": "bamlanivimab (Nov 2020 – US FDA Authorization); bebtelovimab (Feb 2022 – US FDA Authorization); new candidate (Today – 3rd therapeutic antibody for COVID-19 in preclinical development)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "986367f1-ea42-4531-bd2a-d43af27c7672",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.42,
        "x": 0.09,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "Together with our partner, Lilly, AbCellera co-developed two antibody treatments authorized by the US FDA to treat COVID-19.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e67d1a82-e455-4e72-8a54-e1607fbe6471",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.09,
        "y": 0.18
      },
      "kind": "title",
      "text": "FIRST PRE-PARTNERED PROGRAM IN COVID-19 RESULTED IN TREATMENTS FOR ~2.5M PATIENTS",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de26e5e1-c2bd-4c2a-81c0-0222e7f149f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.42,
        "x": 0.09,
        "y": 0.13
      },
      "kind": "title",
      "text": "PRE-PARTNERED PROGRAMS: PANDEMIC RESPONSE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56bfd38e-a831-4c16-ace6-026f7e503129",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "7f920803-1df8-4128-bf16-334fc677bfa9",
      "evidence": "The slide title is in the form of an action title",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 13,
      "beatId": "d1c530ca-0088-4d02-9454-42e31b4ca54f",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides key takeaways and portfolio overview.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 3,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "f61dd81f-4e14-4e3d-a18c-d4800beebb13",
      "evidence": "The document presents a clear pattern of AbCellera's success and potential.",
      "position": 0,
      "objective": "Show the value of AbCellera's technology and portfolio",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    },
    {
      "to": 17,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "96131421-6964-4e15-a1b6-c9e23a66aaed",
      "evidence": "The document implies the cost of inaction in drug development.",
      "position": 1,
      "objective": "Highlight the importance of AbCellera's solution",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}